Evidence map›Paper›PMID 32248435›Full record

ArticleTranslational stroke research2020

Elevated miR-9 in Cerebrospinal Fluid Is Associated with Poor Functional Outcome After Subarachnoid Hemorrhage.

Søren Bache, Rune Rasmussen, Zoe Wolcott, Maria Rossing, Rasmus Møgelvang, Daniel Tolnai, Christian Hassager, Julie L Forman, Lars Køber, Finn Cilius Nielsen and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Translational stroke research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Søren BacheDepartment of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark. bache@dadlnet.dk.
Rune RasmussenDepartment of Neurosurgery, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.
Zoe WolcottDepartment of Neurology & Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Maria RossingCentre for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.
Rasmus MøgelvangDepartment of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen, Denmark.
Daniel TolnaiDepartment of Radiology, The Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.
Christian HassagerDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Julie L FormanSection of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Lars KøberDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Finn Cilius NielsenCentre for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.
William T KimberlyDepartment of Neurology & Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Kirsten MøllerDepartment of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.

Funding

Lundbeckfonden R212-2015-1987Lundbeckfonden (DK) R211-2015-3844
6 · The paper itself

Abstract

This study evaluated microRNA (miRNA) changes in cerebrospinal fluid (CSF) and their association with the occurrence of delayed cerebral ischemia (DCI) and poor functional outcome after SAH. Forty-three selected miRNAs were measured in daily CSF samples from a discovery cohort of SAH patients admitted to Rigshospitalet, Copenhagen, Denmark, and compared with neurologically healthy patients. Findings were validated in CSF from a replication cohort of SAH patients admitted to Massachusetts General Hospital, Boston, Massachusetts. The CSF levels of miRNA over time were compared with the occurrence of DCI, and functional outcome after 3 months. miRNAs were quantified in 427 CSF samples from 63 SAH patients in the discovery cohort, in 104 CSF samples from 63 SAH patients in the replication cohort, and in 11 CSF samples from 11 neurologically healthy patients. The miRNA profile changed remarkably immediately after SAH. Elevated miR-9-3p was associated with a poor functional outcome in the discovery cohort (p < 0.0001) after correction for multiple testing (q < 0.01) and in the replication cohort (p < 0.01). Furthermore, elevated miR-9-5p was associated with a poor functional outcome in the discovery cohort (p < 0.01) after correction for multiple testing (q < 0.05). No miRNA was associated with DCI in both cohorts. miR-9-3p and miR-9-5p are elevated in the CSF following SAH and this elevation is associated with a poor functional outcome. These elevations have potential roles in the progression of cerebral injury and could add to early prognostication.

Indexed as

Recovery of FunctionAdultAgedBiomarkersCohort StudiesFemaleHumansMaleMicroRNAsMiddle AgedPrognosisSubarachnoid HemorrhageBiomarkersMicroRNAsMIRN92 microRNA, humanCerebrospinal fluidMicroRNAStrokeSubarachnoid hemorrhage

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.